Recent Posts in ‘Regenerative Medicine Other News’
Neuralstem And The National Football League Alumni Association Announce Initiative On Brain Injury Treatment
Neuralstem, Inc. (NYSE MKT: CUR) announced that it is working with the National Football League Alumni Association (NFLAA), based in Newark, NJ, to develop a trial for treating NFL alumni members suffering from traumatic brain injuries (TBI), with NSI-189, the lead compound in the company’s neurogenic drug platform. NSI-189, currently in a Phase Ib clinical
InVivo Therapeutics Receives Humanitarian Use Device Designation for Spinal Cord Injury Treatment
InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced that the Company has received approval for its request filed with the U.S. Food and Drug Administration (FDA) for Humanitarian Use Device (HUD) designation for its biopolymer scaffolding product. HUD designation covers
Aastrom Biosciences Announces Strategic Change in Research and Development Programs
Aastrom Biosciences, Inc. (ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today announced a strategic change in its research and development programs to focus on the clinical development of its lead product, ixmyelocel-T, for the treatment of dilated cardiomyopathy (DCM). Aastrom, which recently initiated the Phase
Shire to Acquire SARcode Bioscience, Expands Presence in Ophthalmology
Shire plc (LSE: SHP, NASDAQ: SHPG) today announced that it will acquire SARcode Bioscience Inc., a privately held biopharmaceutical company based in Brisbane, California. This acquisition continues to build Shire’s presence in the ophthalmology therapeutic category and brings a new phase 3 compound – LIFITEGRAST – currently under development for the signs and symptoms of
International Stem Cell Corporation Announces Positive Results of Primate Parkinson’s Study
International Stem Cell Corporation ( OTCQB : ISCO ) (www.internationalstemcell.com) a California-based biotechnology company focused on the therapeutic applications of human parthenogenetic stem cells announced today safety and encouraging efficacy of stem cell therapy in rodent and non-human primate models of Parkinson’s disease. “This pilot study represents a first essential step in bringing cell-based therapies
BioTime Appoints Stephen C. Farrell to Board of Directors
BioTime, Inc. (NYSE MKT: BTX) today announced that Stephen C. Farrell has been appointed to its Board of Directors. “We are pleased to welcome an experienced executive of Steve’s caliber to BioTime’s board,” said Alfred D. Kingsley, Chairman of the Board of BioTime. “Steve adds critical and highly relevant experience as a successful leader and
Cytori Appoints New Executive Vice President and Chief Medical Officer
Cytori Therapeutics (CYTX) has appointed Steven Kesten, MD, as Executive Vice President and Chief Medical Officer. In this role, Dr. Kesten will lead global clinical development operations and Cytori’s Medical Affairs activities. “Dr. Kesten is a seasoned physician executive with more than 30 years of experience in medicine,” said Dr. Hedrick. “This experience includes involvement
Osiris Therapeutics Receives Title of European Orphan Drug Designation for Prochymal®
Osiris Therapeutics, Inc. (OSIR), the leading stem cell company developing and marketing products to treat medical conditions in inflammatory, cardiovascular, orthopedic and wound healing markets, announced today that the European Medicines Agency (EMA) has designated Osiris as the Orphan Drug title holder for Prochymal® (remestemcel-L). The EU Commission adopted the decision to transfer the designation of Prochymal
StemCells, Inc. Announces First Patient Cohort Completion
StemCells, Inc. (STEM) today announced that the twelve-month data from the first patient cohort in the Company’s Phase I/II clinical trial of its proprietary HuCNS-SC(R) product candidate (purified human neural stem cells) for chronic spinal cord injury continued to demonstrate a favorable safety profile, and showed that the considerable gains in sensory function observed in
StemCells, Inc. to Present at 2013 BIO CEO & Investor Conference
StemCells, Inc. (STEM) announced today that President and CEO Martin McGlynn will present an update on the Company’s programs and operations at the 15th Annual BIO CEO & Investor Conference to be held February 11-12 in New York City. Mr. McGlynn is scheduled to speak at 8:30 a.m. Eastern Time on Tuesday, February 12. A live webcast
Stemline Therapeutics, Inc. Announces Closing of Initial Public Offering
Stemline Therapeutics, Inc. (STML), a clinical-stage biopharmaceutical company developing oncology therapeutics that target both cancer stem cells (CSCs) and tumor bulk, announced today the closing of its previously announced initial public offering of 3,815,291 shares of common stock, including the exercise in full of the over-allotment option covering 497,647 shares, at a public offering price of
Vistagen Therapeutics Successfully Completes Final Phase 1 Safety Study of AV-101
VistaGen Therapeutics, Inc. ( OTCQB : VSTA ), a biotechnology company applying stem cell technology for drug rescue, predictive toxicology and drug metabolism screening, today announced the successful completion of its final Phase 1 safety study of AV-101, a novel orally available prodrug candidate being developed for treatment of multiple conditions involving chronic neuropathic pain. The